LBH589

Phase 2Small molecule

Novartis

LBH589 is one of 598 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

597

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

MacroglobulinemiaActive, not recruiting

LymphomaActive, not recruiting

Malignant Pleural MesotheliomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

Diffuse Intrinsic Pontine GliomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

MyelofibrosisActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

GliomaPhase 1/Phase 2

Active, not recruiting

Clear Cell Renal CarcinomaPhase 2

Active, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Malignant Pleural MesotheliomaPhase 1

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 1

Active, not recruiting

Diffuse Intrinsic Pontine GliomaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

MyelofibrosisPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Showing 10 of 20 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Halaven

Eisai

Preclinical

38 3

Tykerb

GSK

Preclinical

80 4

LBH589

Novartis

Phase 2

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

Prolia

14 8

Gemzar

GGynecologic Oncology Group

Preclinical

22 9

Voltaren

Novartis

Preclinical

1 10

Zolymbus

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors4 trials

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

Completed· Novartis logo

Novartis·Phase 1·NCT00503451·14 enrolled

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

Completed· Novartis logo

Novartis·Phase 1·NCT01007968·25 enrolled

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Completed· Novartis logo

Novartis·Phase 1·NCT00570284·36 enrolled

Show 1 more trial

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

Completed· Novartis logo

Novartis·Phase 1·NCT00739414·14 enrolled

Multiple Myeloma4 trials

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

Completed· Novartis logo

Novartis·Phase 1·NCT00532389·62 enrolled

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Terminated· Novartis logo

Novartis·Phase 2·NCT00445068·38 enrolled

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Completed· Novartis logo

Novartis·Phase 2·NCT02290431·31 enrolled

Show 1 more trial

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Completed· Novartis logo

Novartis·Phase 1·NCT00532675·46 enrolled

Lymphoma2 trials

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

Completed·SSarit Assouline·Phase 2·NCT01238692·42 enrolled

Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT01032148·8 enrolled

Breast Cancer2 trials

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT00788931·15 enrolled

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT00632489·20 enrolled

Myeloid Leukemia2 trials

Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase

Terminated· Novartis logo

Novartis·Phase 2·NCT00451035·29 enrolled

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Terminated· Novartis logo

Novartis·Phase 2·NCT00449761·27 enrolled

21 more indications

Myelodysplastic Syndromes2 trials

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Terminated· Novartis logo

Novartis·Phase 2·NCT01034657·34 enrolled

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Completed·WWashington University School of Medicine·Phase 1/2·NCT00691938·52 enrolled

Absorption1 trial

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

Completed· Novartis logo

Novartis·Phase 1·NCT00472368·4 enrolled

Glioma1 trial

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Completed·PPatrick Y. Wen, MD·Phase 1/2·NCT00859222·51 enrolled

Thyroid Cancer1 trial

Trial of LBH589 in Metastatic Thyroid Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01013597·13 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated·—·Phase 2·NCT00978432·50 enrolled

Myelodysplastic Syndrome1 trial

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00939159·17 enrolled

Colorectal Cancer1 trial

Phase II Trial of LBH589 in Refractory Colorectal Cancer

Completed·SSwedish Medical Center·Phase 2·NCT00690677·29 enrolled

Prostate Cancer1 trial

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT00663832·44 enrolled

Soft Tissue Sarcoma1 trial

Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure

Completed·CCentre Leon Berard·Phase 2·NCT01136499·53 enrolled

Chronic Lymphocytic Leukemia1 trial

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01090973·1 enrolled

Metastatic Melanoma1 trial

Panobinostat (LBH589) in Patients With Metastatic Melanoma

Completed·—·Phase 1·NCT01065467·16 enrolled

Myelofibrosis1 trial

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Unknown status·RRonald Hoffman·Phase 1/2·NCT01298934·22 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Completed·PPediatric Brain Tumor Consortium·Phase 1·NCT02717455·53 enrolled

Intravenous1 trial

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

Terminated· Novartis logo

Novartis·Phase 1·NCT00419536·108 enrolled

Macroglobulinemia1 trial

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Completed·—·Phase 2·NCT00936611·39 enrolled

Clear Cell Renal Carcinoma1 trial

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00550277·20 enrolled

Cutaneous T-cell lymphoma1 trial

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

Completed· Novartis logo

Novartis·Phase 1·NCT00412997·14 enrolled

Chronic Graft Versus Host Disease1 trial

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

Withdrawn·SSCRI Development Innovations, LLC·Phase 2·NCT01028313

Hematological Malignancies1 trial

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

Completed· Novartis logo

Novartis·Phase 1/2·NCT00621244·175 enrolled

Malignant Pleural Mesothelioma1 trial

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Completed· Novartis logo

Novartis·Phase 1·NCT00535951·18 enrolled

Unspecified1 trial

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Terminated· Novartis logo

Novartis·Phase 1·NCT00493766·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 36 trial records for LBH589. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LBH589 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LBH589. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

LBH589

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Patients With Advanced Solid Tumors4 trials

Multiple Myeloma4 trials

Lymphoma2 trials

Breast Cancer2 trials

Myeloid Leukemia2 trials

Myelodysplastic Syndromes2 trials

Absorption1 trial

Glioma1 trial

Thyroid Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Myelodysplastic Syndrome1 trial

Colorectal Cancer1 trial

Prostate Cancer1 trial

Soft Tissue Sarcoma1 trial

Chronic Lymphocytic Leukemia1 trial

Metastatic Melanoma1 trial

Myelofibrosis1 trial

Diffuse Intrinsic Pontine Glioma1 trial

Intravenous1 trial

Macroglobulinemia1 trial

Clear Cell Renal Carcinoma1 trial

Cutaneous T-cell lymphoma1 trial

Chronic Graft Versus Host Disease1 trial

Hematological Malignancies1 trial

Malignant Pleural Mesothelioma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News